louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05280080: Exercise With Dual Task in Knee Osteoarthritis
Official title: Neuromuscular and Perceptual Responses, Pain Intensity and Performance During Resistance Exercise With a Self-regulated Dual-task in Patients With Severe Knee Osteoarthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Knee Osteoarthritis
Keywords: Knee Osteoarthritis
Electromyography
Muscle Activity
Resistance Training
Lead sponsor: University of Valencia
Sponsor class: OTHER
First posted: 2022-03-15
Enrollment: 25
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the neuromuscular and perceptual responses, pain intensity and performance in patients with severe knee osteoarthritis in a preoperative setting with low-load resistance training with a self-regulated mathematical dual-task.


Eligibility criteria: Inclusion Criteria:

* men and women above 55 years old.
* diagnosed with severe knee osteoarthritis.
* scheduled for unilateral TKA surgery in a local hospital during 2021- 2022.

Exclusion Criteria:

* pain in the contralateral limb (maximum pain, ≥80 of 100 mm on a VAS during daily activities).
* another hip or knee joint replacement in the previous year.
* any medical condition in which exercise was contraindicated.
* participated in exercise programs (\>2 days/week, training at intensities of 10-15RM) in the 6 months prior to the study.
* history of stroke, brain surgery, major depression, or any self-perceived cognitive alterations that could affect the performance of dual tasks.

Primary outcomes:
measure: Self-reported pain intensity (Visual Analogue Scale (VAS) Scale 0-10)
timeFrame: Pre exercise, immediate post session, and 10 minutes after session.
measure: Pressure pain thresholds
timeFrame: Pre exercise, immediate post session, and 10 minutes after session.
measure: HDsEMG
timeFrame: During each experimental session and during each exercise condition.
measure: Performance
timeFrame: During each experimental session and during each exercise condition.
Secondary outcomes:
measure: Tampa Scale of Kinesiophobia (TSK 11)
timeFrame: Pre session.
measure: Pain Catastrophizing Scale (PCS)
timeFrame: Pre session.
measure: Chronic Pain Self-Efficacy Scale (CPSS)
timeFrame: Pre session.
measure: WOMAC questionaire for patients with hip or knee osteoarthritis.
timeFrame: Pre session.
measure: Heart Rate
timeFrame: Pre exercise, immediate post session, and 10 minutes after session.
measure: Perceived difficulty of the dual-task.
timeFrame: Immediate post exercise.
Other outcomes:
Locations:
city: Valencia
country: Spain
facility: Clinic Universitary Hospital of Valencia
Study officials:
affiliation: University of Valencia
name: José Casaña
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Valencia
name: Joaquín Calatayud
role: STUDY_CHAIR
References:
Clinical trial NCT06245980: Role of SGLT2I in Patients With Myocardial Infarction
Official title: Role of SGLT2I in Diabetic Patients With Myocardial Infarction
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Myocardial Infarction
Diabetes Mellitus
Lead sponsor: Chongqing Medical University
Sponsor class: OTHER
First posted: 2024-02-07
Enrollment: 1200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Acute myocardial infarction patients with diabetes mellitus

Brief summary: Role of sglt2I in diabetic patients with myocardial infarction


Eligibility criteria: Inclusion Criteria:

1. Acute myocardial infarction patients
2. Type 2 diabetics.

Exclusion Criteria:

1. Patients undergoing coronary artery bypass grafting (CABG).
2. Severe valvular heart disease.
3. Contraindications of secondary medical preventive therapy for myocardial infarction, such as β-blockers, angiotensin-converting enzyme inhibitors (ACEI)/ angiotensin-converting enzyme inhibitors (ARBs), antiplatelets, and statins.
4. Previously used SGLT2i.
5. Severe hepatic and renal insufficiency.

Primary outcomes:
measure: MACE
timeFrame: 24months
measure: Heart failure readmission
timeFrame: 24months
Secondary outcomes:
measure: Recurrent myocardial infarction
timeFrame: 24months
measure: cardiovascular death
timeFrame: 24months
Other outcomes:
Locations:
city: Chongqing
country: China
facility: The First Affiliated Hospital of Chongqing Medical University
state: Chongqing
Study officials:
References:
Clinical trial NCT06252480: Effect of Various Intensities of tDCS on Dual Task Cognitive Functions in Normal Subjects
Official title: Effect of Various Intensities of tDCS on Dual Task Cognitive Functions in Normal Subjects: A Pilot Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cognitive Functions
Lead sponsor: Maharishi Markendeswar University (Deemed to be University)
Sponsor class: OTHER
First posted: 2024-02-09
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 26
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Transcranial Direct Current Stimulation (tDCS) is a neuroregulatory method that delivers a weak straight tendency to neuronal areas with the intention of changing the brain's basic metabolic processes. Degradation of executive performance may not necessarily arise from cathodal stimulation, and vice versa for anodal stimulation.

Detailed description: Total 48 samples were taken, were randomly allocated into an experimental group of 4 variance of different intensities of tDCS. At F3 and F4, tDCS was applied to the desired region. Electrodes were put in using the 10-20 EEG technique throughout the parietal cortex, with the current electrode being set on F3 area and control electrode being positioned on the F4 area. For 20 minutes over three days per week for up to three weeks, current intensities of 0.5mA for group A, 1.0mA for group B, 1.5mA for group C, and 2.0mA for group D were administered. when engaging in dual-task cognitive processes. The groups are going to receive 9 sessions of tDCS treatment. The MoCA and TMT scale was completed by samples before and after the intervention. Finally, specifics investigation will be carried out using SPSS 26.0 software.

Eligibility criteria: Inclusion Criteria:

* Physically healthy students only
* Willing to participate in the study

Exclusion Criteria:

* Any recent trauma or injury on the head of subjects
* If contact with the scalp is not possible
* Any resonant implant close to electrode placement site

Primary outcomes:
measure: MoCA
timeFrame: 10 mins
Secondary outcomes:
measure: TRAIL MAKING TEST
timeFrame: 3 minutes
Other outcomes:
Locations:
city: Ambala
country: India
facility: MMIPR
state: Haryana
Study officials:
affiliation: Maharishi Markendeshwar Institute of Physiotherapy and Rehabilitation, Ambala, Haryana, 133207
name: Subhashish Chatterjee, MPT(NEURO)
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00765180: Comparison of Transparent Retractable Extension Device and Narrow Band Imaging on Colorectal Adenoma Detection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colorectal Cancer Screening
Keywords: colonoscopy
hood
NBI
Lead sponsor: Showa Inan General Hospital
Sponsor class: OTHER
First posted: 2008-10-02
Enrollment: 200
Sex: ALL
Minimum age (years): 20
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The investigators previously reported that colonoscopy with a transparent retractable extension (TRE) device improved the adenoma detection rate without affecting intubation and withdrawal times. On the other hand, colonoscopy using narrow band imaging (NBI) is expected to lead to higher rate s of adenoma detection. The investigators compared the effects of TRE device on colorectal adenoma detection with those of NBI.


Eligibility criteria: Exclusion Criteria:

* Age less than 20 years old
* Pregnant
* American Society of Anesthesiologists class III and IV
* Overweight (body weight \> 100 kg)
* Allergic to the drugs used or its components (soybeans or eggs)
* Poor bowel preparation
* Previous colorectal surgical resection

Primary outcomes:
measure: Colorectal adenoma detection rate
timeFrame: after colonoscopy
Secondary outcomes:
measure: Procedure time, complication
timeFrame: after colonoscopy
Other outcomes:
Locations:
city: Komagane
country: Japan
facility: Showa Inan General hospital
state: Nagano
Study officials:
References:
Clinical trial NCT04710680: Reasons for Nonattendance Inpatient Colonoscopy
Official title: Reasons for Nonattendance Inpatient Colonoscopy: a Cross-sectional Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Colonoscopy Nonattendance
Inpatient
Lead sponsor: Ningbo No. 1 Hospital
Sponsor class: OTHER
First posted: 2021-01-15
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1. inpatients undergoing colonoscopy.
2. inpatients older than 18 years

Brief summary: The absence of colonoscopy is a clinical problem that can't be ignored. According to previous studies, the absence rate for outpatient colonoscopy is between 4% and 29%. The aim of this study is to determine the reasons for colonoscopy appointment cancellations among inpatients and to identify the factors associated with colonoscopy nonattendance.


Eligibility criteria: Inclusion Criteria:

* inpatients older than 18 years.
* inpatients undergoing colonoscopy

Exclusion Criteria:

* Emergency colonoscopy.
* Pregnant or breastfeeding.
* Lack of complete data.

Primary outcomes:
measure: nonattendance rate of colonoscopy appointment
timeFrame: 1 Day of colonoscopy
Secondary outcomes:
measure: reason for colonoscopy cancellation
timeFrame: 1 Day of colonoscopy
Other outcomes:
Locations:
city: Ningbo
country: China
facility: Ningbo First Hospital
state: Zhejiang
Study officials:
References:
Clinical trial NCT03869580: Incidence and Factors Associated With Double-J Urinary Stent Infection (IJJ)
Official title: Incidence and Factors Associated With Double-J Urinary Stent Infection (IJJ)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Double J Stent
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
First posted: 2019-03-11
Enrollment: 800
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients with a double-J stent placement or change in the hospital will be included.

Follow-up will be repeated at 1, 3 and 6 months and urinary tract infection will be reported

Brief summary: The aim of the study was to determine the incidence and factors associated with double-J urinary stent infection.


Eligibility criteria: Inclusion Criteria:

* Patients with a double-J stent placement or change in the hospital

Exclusion Criteria:

* renal transplants less than one year old

Primary outcomes:
measure: Number of patients with urinary tract infection associated with double J stent
timeFrame: 6 months
measure: Number of patients with specific clinical data associated with urinary tract infection associated with double J stent
timeFrame: 6 months
Secondary outcomes:
measure: Number of patients with relapse and/or recurrence after a first urinary tract infection
timeFrame: 6 months
Other outcomes:
Locations:
city: Besançon
country: France
facility: CHU de Besançon
Study officials:
References:
Clinical trial NCT03890380: Safety and Performance Evaluation of the Magneto Wire
Official title: Safety and Performance Evaluation of the Magneto Wire
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Ischemic Stroke
Lead sponsor: Magneto Thrombectomy Solutions
Sponsor class: INDUSTRY
First posted: 2019-03-26
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A prospective, open label single arm feasibility study to evaluate the safety and performance of the Magneto Wire in patients diagnosed with acute ischemic stroke and planned for thrombectomy procedure.


Eligibility criteria: Inclusion Criteria:

* Acute ischemic stroke within defined timelines.
* Age 18-85 years old
* NIHSS ≥ 8
* No significant pre-stroke functional disability (mRS ≤ 1)

Exclusion Criteria:

* Life expectancy of less than 90 days
* Neurological signs that are rapidly improving prior to or at time of treatment
* NIHSS≥30 or state of coma
* Ongoing seizure
* Current use of cocaine or other vasoactive substance
* Known bleeding diathesis
* Known hemorrhagic or coagulation deficiency
* Evidence of active systemic infection
* Current use of oral anticoagulants INR \> 3
* Administration of heparin or Novel Oral Anticoagulants within 48 hours preceding the onset of stroke and have an abnormal aPTT at presentation
* Platelet count \< 50,000/mm3
* Glucose \<50 mg/dL (2.8 mmol, 2.6mM)
* Uncontrolled hypertension (SBP\>185 or DBP\>110) refractory to pharmacological management
* Known hypersensitivity or allergy to radiographic contrast agents
* Pregnancy or lactating female
* Subject already enrolled in a clinical study involving experimental medication or device
* CT scan or MRI with evidence of acute intracranial hemorrhage, ASPECT score\<6, mass effect and/or intracranial tumor.
* Angiographic evidence of carotid dissection, or high grade stenosis that will prevent access to the clot, or cerebral vasculitis, or intracranial stenosis
* Blood vessel with extreme tortuosity or other conditions preventing the access of the device.
* Angiographic evidence of carotid dissection, complete cervical carotid occlusions or vasculitis.

Primary outcomes:
measure: Safety Assessment
timeFrame: 24 (±8) hours post procedure
Secondary outcomes:
measure: Safety Assessment
timeFrame: 90 (±10) days
measure: Revascularization
timeFrame: immediate
measure: Distal Embolism
timeFrame: immediate
measure: National Institutes of Health Stroke Scale (NIHSS)
timeFrame: 24 (±8) hours post procedure
measure: Modified Rankin Scale
timeFrame: 90 (±10) days
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam Health Care Campus
Study officials:
affiliation: Magneto Thrombectomy Solutions
name: Shally Sharon
role: STUDY_DIRECTOR
References:
Clinical trial NCT02436980: Premedication for ERCP With Midazolam or Tramadol
Official title: Effects of Midazolam or Tramadol Premedication on Early Cognitive Function in ERCP: a Randomized Controlled Double-Blind Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Chronic Disease
Keywords: premedication
ERCP
midazolam
tramadol
cognitive
Lead sponsor: Karadeniz Technical University
Sponsor class: OTHER
First posted: 2015-05-07
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: OBJECTIVE:Purpose of this study is to set forth the sedative efficacy and effects on early period cognitive functions of two premedication drugs used for ERCP (Endoscopic retrograde cholangiopancreatography) METHODS:This randomized and double blind study was performed with forty (18-70 of age) ASA I-III risk group patients for who elective ERCP was planned. Cognitive functions of patients were determined by mini-mental test (MMT). 0.5 mg/kg midazolam or 1mg/kg tramadol drop was administered orally before intervention to patients who were randomly divided into two premedication groups.

Vital signs,BIS (Bispectral index), mRSS (modified Ramsay Sedation scale), NRS (numeric rating scale ) was evaluated. If MMT (mini-mental test) was ≤ 23 at 60th minute it was considered as cognitive impairment. Recovery period, post-procedure state of cognitive function at 60th minute were recorded.

Detailed description: The Outcome Measures are number of Participants with Adverse Events, and the incidence of Postoperative cognitive dysfunction assessed by MMT (mini-mental test) in first 60 minutes.

Eligibility criteria: Inclusion Criteria:

* This study was conducted in the Endoscopy Department for forty (18-70 years old) outpatients in ASA I-III risk group were randomized and double blind planned for elective ERCP.

Exclusion Criteria:

* American Society of Anesthesiologist (ASA) class greater than 3,
* morbid obesity,
* major organ dysfunction (respiratory, renal and hepatic),
* history of drug addiction,
* known hypersensitivity for tramadol, midazolam and remifentanil,
* mini-mental test (MMT) ≤ 23 or
* refusal of the patient.

Primary outcomes:
measure: The early cognitive functions after ERCP
timeFrame: Postprocedure in the first 60 minutes
Secondary outcomes:
measure: Number of Participants with Adverse Events
timeFrame: Postprocedure in first 60 minutes
Other outcomes:
Locations:
Study officials:
affiliation: Gastroenterology Department
name: Mehmet Arslan, Prof.Dr.
role: STUDY_CHAIR
References:
Clinical trial NCT04004962: Use of Infrared Spectroscopy in Fast Septic Arthritis Diagnosis
Official title: Use of Infrared Spectroscopy in Fast Septic Arthritis Diagnosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Joint Effusion
Lead sponsor: Rennes University Hospital
Sponsor class: OTHER
First posted: 2019-07-02
Enrollment: 360
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients benefiting from joint fluid puncture for diagnostic purposes in the rheumatology hospitals participating in the study

Brief summary: To study the diagnostic performance of infrared spectroscopy on fresh synovial fluids in early septic arthritis diagnosis in patients with acute joint effusion

Detailed description: Diagnosis of a joint effusion is frequently a medical emergency, especially when septic arthritis is suspected. Septic arthritis diagnosis relies on microscopic and bacteriological analysis of synovial fluid obtained by arthrocentesis. Direct microscopic examination can be made within 2 to 12 hours but it is negative in about 50 % of the cases. It is necessary to wait 72 hours to obtain the result of the culture and reasonably rule out the diagnosis of septic arthritis. A method of establishing an immediate etiological diagnosis could improve the care of patients with joint effusion that is a therapeutic emergency and justify a hospitalization and a parenteral antibiotic therapy.

Eligibility criteria: Inclusion Criteria:

* patients over 18 year old
* patients with an acute arthritis defined by an evolution of less than 6 weeks
* patients benefiting from joint fluid puncture for diagnostic purposes in the rheumatology hospitals participating in the study
* patients who received information about the protocol and have not expressed opposition to participate

Exclusion Criteria:

* patients opposing the study
* protected major (safeguard justice, trusteeship and guardianship) and persons deprived of liberty

Primary outcomes:
measure: Diagnosis of the cause of joint effusion
timeFrame: Up to 7 days (time to perform Spectroscopy and collect laboratory results)
Secondary outcomes:
measure: Number of days of hospitalization
timeFrame: Up to 2 months (time to collect data on hospitalization duration and antibiotic therapy duration)
measure: Total dose of antibiotics
timeFrame: Up to 2 months (time to collect data on hospitalization duration and antibiotic therapy duration)
Other outcomes:
Locations:
city: Angers
country: France
facility: CHU Angers
city: Brest
country: France
facility: CHRU Brest
city: Clermont-Ferrand
country: France
facility: CHU Clermont-Ferrand
city: Nantes
country: France
facility: CHU Nantes
city: Rennes
country: France
facility: CHU de Rennes
city: Tours
country: France
facility: CHRU Tours
Study officials:
References:
Clinical trial NCT02637362: Optimal Analgesia for Forefoot Surgery
Official title: Optimal Analgesia Following Metatarsal Surgery: A Prospective Randomised, Single-Blind Sham-Controlled Trial of Three Strategies
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hallux Valgus
Conduction Block
Lead sponsor: Queen Elizabeth Hospital NHS Foundation Trust
Sponsor class: OTHER
First posted: 2015-12-22
Enrollment: 69
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A randomised trial comparing three analgesic strategies for patients undergoing forefoot surgery in a day-surgery setting.

Detailed description: Forefoot surgery, including Scarf-Akin osteotomy surgery for bunion correction, is moderately painful orthopaedic surgery, commonly performed as a day-case procedure. Admission for opiate analgesia constitutes a failure of management and financial disadvantage to the healthcare organisation. The investigators seek to establish which technique will result in the best analgesia out of ankle block, metatarsal block, or a combination of the two. As analgesia constitutes part of a return to function, an additional aim is to determine whether either of these approaches will result in an objective functional benefit to the participants.

The trial seeks to recruit 23 patients into either of 3 groups: Ankle + sham metatarsal; sham Ankle + metatarsal; Ankle + Metatarsal.

Eligibility criteria: Inclusion Criteria:

* Participant is willing and able to give informed consent for participation in the study.
* Male or female, aged 18 years or above.
* Diagnosed with 1st metatarsal pathology requiring surgical correction
* Participant meets the criteria for operative management in our day-surgery unit

Exclusion Criteria:

* Contraindication to general anaesthesia
* Diabetic neuropathy affecting lower limbs
* Peripheral neuropathy affecting lower limbs of any aetiology
* Revision surgery
* Lack of capacity to consent

Primary outcomes:
measure: Static pain score
timeFrame: 6 hours post-operatively
Secondary outcomes:
measure: Dynamic pain scores
timeFrame: 6 hours post-operatively
measure: Dynamic pain scores
timeFrame: Day 1 post-operatively
measure: Dynamic pain scores
timeFrame: Day 7 post-operatively
measure: Assessment of functional recovery
timeFrame: 6 hours post-operatively
measure: Assessment of functional recovery
timeFrame: Day 1 post-operatively
measure: Assessment of functional recovery
timeFrame: Day 7 post-operatively
measure: Static pain score
timeFrame: Day 1 post-operatively
measure: Static pain score
timeFrame: Day 7 post-operatively
Other outcomes:
Locations:
city: King's Lynn
country: United Kingdom
facility: Queen Elizabeth Hospital NHS Trust
state: Norfolk
Study officials:
References: